Inverness Medical Innovations Inc. hopes to raise $200 million, in part to pay off some of the nut from its Acon Labs acquisition, via a public offering of senior subordinated notes.

When they come due in 2016, the Waltham diagnostics maker said certain of its subsidiaries will make the payouts.

In an April 10 filing with the federal Securities and Exchange Commission, Inverness said it planned to use the proceeds for working capital, including “to pay some or all of our remaining obligations relating to our recently completed acquisition of the second territory business from Acon.”

Perhaps coincidentally, the company’s 2006 deal to buy portions of Acon Laboratories Inc., a San Diego-based rapid diagnostics test maker, wound up closing for about $200 million.

Inverness posted strong first-quarter numbers last week, logging a nearly 20 percent sales jump to $444 million and transforming its $4.2 million net loss from the 2008 first quarter to $6.3 million in Q1 profits this year.

Those results, and news that Inverness might be in line to supply the test used to diagnose so-called Swine Flu, sent the company’s stock price up $3 per share to $31.75. As of about 10 a.m. May 4, shares were trading at $31.82 after opening at $32.04.